In patients with T2DM, GLP-1 RAs are associated with a significant 12-14% reduction in three-point composite MACE outcome consisting of cardiovascular mortality, non-fatal MI, and non-fatal stroke compared to placebo. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.